BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients

Drug discovery,drug target discovery,aggressive,drug-resistant cancer,axl,oncology,acute myeloid leukaemia,and non-small cell lung cancer

Bergenbio asa operates in the Biotechnology research industry.

Bergenbio asa's revenue is < 1m

Bergenbio asa has 11 - 50 employees.